Day, JW;
Fox, TA;
Halsey, R;
Carpenter, B;
Kottaridis, PD;
(2020)
IL-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
British Journal of Haematology
, 190
(2)
e80-e83.
10.1111/bjh.16873.
Preview |
Text
bjh.16873.pdf - Accepted Version Download (1MB) | Preview |
Abstract
As of 17th May, 2020 the number of patients infected by coronavirus disease 2019 (COVID-19) worldwide has exceeded 4.5 million (WHO 2020). A subgroup of patients with COVID-19 pneumonia develop a hyperinflammatory syndrome which has a similar cytokine release profile to secondary haemophagocytic lymphohistiocytosis (HLH) (Huang, et al 2020). Immunomodulatory drugs are hypothesised to abrogate the dysfunctional immune response in hyperinflammatory COVID-19 and are currently being investigated in clinical trials. IL-1 blockage with anakinra has been shown to be safe and is associated with clinical improvement in patients with hyperinflammatory COVID-19 (Cavalli, et al 2020).
Type: | Article |
---|---|
Title: | IL-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement |
Location: | England |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1111/bjh.16873 |
Publisher version: | https://doi.org/10.1111/bjh.16873 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
URI: | https://discovery.ucl.ac.uk/id/eprint/10098766 |




Archive Staff Only
![]() |
View Item |